J&J Contractor Plans to Resume COVID-19 Vaccine Production at Baltimore Plant – WSJ | U.S. News®

J&J Contractor Plans to Resume COVID-19 Vaccine Production at Baltimore Plant – WSJ | U.S. News®

(Reuters) – Johnson & Johnson contractor Emergent Biosolutions Inc plans to resume COVID-19 vaccine production at its Baltimore plant after getting approval from the U.S. Food and Drug Administration (FDA), the Wall Street Journal reported https://on.wsj.com/3iXSAfg late on Wednesday, citing a statement from the company and a FDA letter.

J&J, Emergent and the FDA did not immediately respond to Reuters requests for comment.

(Reporting by Aishwarya Nair in Bengaluru; Editing by Subhranshu Sahu)

Copyright 2021 Thomson Reuters.

cloudnewsmag

Blogger with swag

Leave a Reply

Your email address will not be published. Required fields are marked *

%d bloggers like this: